Suppr超能文献

相似文献

1
The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer.
J Sex Med. 2022 Mar;19(3):471-478. doi: 10.1016/j.jsxm.2022.01.003. Epub 2022 Feb 5.
2
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
J Sex Med. 2019 Jun;16(6):872-879. doi: 10.1016/j.jsxm.2019.03.273. Epub 2019 May 9.
3
Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
J Sex Med. 2014 Nov;11(11):2818-25. doi: 10.1111/jsm.12657. Epub 2014 Aug 18.
4
Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
J Sex Med. 2021 Aug;18(8):1346-1353. doi: 10.1016/j.jsxm.2021.06.007. Epub 2021 Jul 22.
6
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23.
9
The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction.
J Sex Med. 2010 Jan;7(1 Pt 1):284-92. doi: 10.1111/j.1743-6109.2009.01549.x. Epub 2009 Nov 13.

引用本文的文献

2
Associating serum testosterone levels with African ancestral prostate cancer health disparities.
Sci Rep. 2025 Apr 8;15(1):12013. doi: 10.1038/s41598-025-92539-y.
3
Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer.
Front Oncol. 2025 Mar 19;15:1520370. doi: 10.3389/fonc.2025.1520370. eCollection 2025.
4
Clinical evaluation and treatment in men with low testosterone levels and prostate cancer.
Actas Urol Esp (Engl Ed). 2024 Jul-Aug;48(6):410-415. doi: 10.1016/j.acuroe.2023.12.001. Epub 2023 Dec 13.
6
The most effective but largely ignored target for prostate cancer early detection and intervention.
J Cancer. 2022 Oct 17;13(13):3463-3475. doi: 10.7150/jca.72973. eCollection 2022.
7
The Pre-Testosterone Therapy Checklist.
J Sex Med. 2022 Aug;19(8):1214-1217. doi: 10.1016/j.jsxm.2022.03.619. Epub 2022 May 2.

本文引用的文献

1
Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease.
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):689-695. doi: 10.1038/s41391-020-0241-3. Epub 2020 Jun 8.
2
Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy.
BJU Int. 2020 Jul;126(1):91-96. doi: 10.1111/bju.15042. Epub 2020 Apr 1.
3
Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6238-6246. doi: 10.1210/jc.2019-00806.
4
Testosterone Deficiency: A Review and Comparison of Current Guidelines.
J Sex Med. 2019 Jun;16(6):812-820. doi: 10.1016/j.jsxm.2019.03.262. Epub 2019 May 9.
5
Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
Eur Urol. 2018 Nov;74(5):585-594. doi: 10.1016/j.eururo.2018.07.024. Epub 2018 Aug 1.
6
Evaluation and Management of Testosterone Deficiency: AUA Guideline.
J Urol. 2018 Aug;200(2):423-432. doi: 10.1016/j.juro.2018.03.115. Epub 2018 Mar 28.
7
History of the discovery and clinical translation of prostate-specific antigen.
Asian J Urol. 2014 Oct;1(1):12-14. doi: 10.1016/j.ajur.2014.09.008. Epub 2015 Apr 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验